2nd Novel Nasal Formulation And Delivery Summit

Join us as we delve into the latest breakthroughs in formulation development, intricate API delivery, and device compatibility, all designed to harness the potential of this non-invasive delivery route for enhanced patient convenience and compliance.

Irrespective of your primary disease focus, this summit serves as your comprehensive resource to optimize your nasal pipeline and elevate bioavailability for cutting-edge next-generation therapeutics. We'll explore the technical and scientific intricacies, including the innovative use of particle engineering to achieve cellular penetration across the mucus membranes and the blood-brain barrier.

Don't forgo this opportunity to shape the future of accessible drug products - join us now to maximize therapeutic efficacy and expand the reach of intranasal administration!

What's new for 2024?
- 2 deep-dive workshops where you can engage in fruitful discussions around advancing drug-device synergy early on in your studies and maintaining immune response for nasal vaccine applications for long-lasting potency
- Case studies highlighting the use of novel formulations including nano and micro-particles to gain access to your target of interest
- Key lessons learned in tailoring your formulation strategy for large and small APIs, considering permeability, bioavailability, and stability for enhanced targeted delivery

URL:
Tickets: https://go.evvnt.com/2241656-0?pid=10018

Prices:
Conference + 2 Workshops - Drug Developer Rate: USD 4097.00,
Conference + 1 Workshop - Drug Developer Rate: USD 3498.00,
Conference Only - Drug Developer Rate: USD 2899.00,
Conference + 2 Workshops - Solution Provider Pricing: USD 4997.00,
Conference + 1 Workshop - Solution Provider Pricing: USD 4298.00,
Conference Only - Solution Provider Pricing: USD 3599.00,
Conference + 2 Workshops - Academic Pricing: USD 3497.00,
Conference + 1 Workshop - Academic Pricing: USD 2998.00,
Conference Only - Academic Pricing: USD 2499.00

Speakers: Lillian Li, CMC Product and Device Lead, Sanofi Pasteur, Eric Kaneps, Vice President, Sales and Marketing, Renaissance, Maria Smith Director, Application and Business Development, Proveris Scientific, Marcel Sachs, Product Line Manager Healthcare, Silgan Dispensing, Reenal Gandhi, Director Business Development, Aptar Pharma, Mike Redmond, Chief Operating Officer, Oragenics, Kapileswar Swain, Director and Head of Research and Development Site Nasal, Inhalation, Opthalmic and Other Liquid Products Development, Apotex, Andrew Martin, Professor, Mechanical and Biomedical Engineering, University of Alberta, Craig Behnke, Executive Vice President - Production and Development, Lumen Bioscience, John Marshall, Chief Scientific Officer, Beyond Barriers Therapeutics, Krishna Subramanian, Vice President and Head of Non-Clinical and Translational Science, Seelos Therapeutics, Laleh Golshahi, Professor, Virgina Commonwealth University, Michael G. Palfreyman, President Palfreyman, BioPharm Advisors, Michel Baudry, Chief Scientific Officer, NeurAegis, Robert Thorne, Denali Fellow, Head of Postdoc Program, Denali Therapeutics, Ryan Kole, Chief Executive Officer, Beyond Barriers Therapeutics, Stella Sung, Chief Executive Officer, NeurAegis, Stuart Madden. Chief Scientific Officer, Neurelis, Thomas Bradshaw, Chief Executive Officer, Neuronasal, Whitney Shatz-Binder, Principal Scientist, Genentech, Zachary Warnken, Director, Pharmaceutical Development, Via Therapeutics